Current status: TRIUMPH-4 results available: December 2025 readout showing 28.7% weight loss at 68 weeks (Giblin et al., PMID 41090431) Additional TRIUMPH trials: Expected to report results through 2026, including TRIUMPH-Outcomes (cardiovascular endpoints, NCT06383390, completion Feb 2029) NDA submission timing: Eli Lilly must compile the full trial package before submitting
4-6 treatments are recommended 4-6 weeks apart
Early studies indicate GLP-1s should be researched further as possible treatments for alcohol use and substance use disorders, nicotine addiction, and compulsive behaviors
That is a fundamentally different goal than "lose weight as fast as possible." It's harder, slower on the scale, and produces dramatically better results in the mirror and in long-term health
Try HUMs Flatter Me Fiber GLP-1 Booster for Free Apply Now
While individually effective, the co-administration of BPC-157 and TB-500 may produce more robust regenerative outcomes by targeting both the structural and signaling components of tissue repair